Why Is Amifampridine (Firdapse) So Hard to Find? [Explained for 2026]

If you or a loved one has been diagnosed with Lambert-Eaton Myasthenic Syndrome (LEMS) and your doctor prescribed Firdapse (amifampridine), you may have quickly discovered that finding it at a regular pharmacy is nearly impossible. You're not imagining things — amifampridine is one of the most difficult specialty medications to access in the United States. Here's why, and what you can do about it.

What Is Amifampridine and Why Is It Special?

Amifampridine (brand name Firdapse) is an FDA-approved oral treatment for Lambert-Eaton Myasthenic Syndrome, a rare autoimmune disorder of the neuromuscular junction. LEMS affects an estimated 1 in 100,000 people in the United States — making it one of the rarest conditions for which a dedicated treatment exists.

Because LEMS is so rare, Firdapse carries orphan drug designation from the FDA. This means it was developed specifically for a rare disease, and the manufacturer — Catalyst Pharmaceuticals — benefits from regulatory incentives and market exclusivity. The drug is not a controlled substance, but its rarity and high price ($31,000–$34,000 for 120 tablets at list price) mean it's handled very differently from typical prescriptions.

Why Most Retail Pharmacies Don't Carry It

Your neighborhood CVS, Walgreens, or Rite Aid almost certainly doesn't stock amifampridine — and there's a straightforward reason for that. Retail pharmacies purchase medications based on expected demand. When a drug treats a condition affecting only a tiny fraction of the population, there's no economic reason to keep it on the shelf. Stocking an $30,000+ specialty medication that might sit unsold for months simply doesn't make sense for a retail pharmacy.

Instead, amifampridine is dispensed exclusively through specialty pharmacies — specialized dispensers that are equipped to handle complex, high-cost medications for rare diseases. These pharmacies have dedicated teams to manage prior authorization paperwork, copay assistance programs, and patient support services.

The Specialty Pharmacy Requirement

Insurance companies and the manufacturer require that amifampridine be dispensed through in-network specialty pharmacies. This isn't arbitrary — specialty pharmacies provide critical services for complex medications:

Prior authorization management and appeals support

Patient assistance program enrollment (Catalyst Pathways)

Specialized storage and shipping conditions

Clinical monitoring and refill coordination

Coordination with your neurologist or prescriber

If your regular pharmacy is trying to order amifampridine and running into walls, it's because they aren't set up in the specialty pharmacy network for this medication. Your prescriber will need to send the prescription to an approved specialty pharmacy.

Prior Authorization Adds Delays

Even once you've located the right specialty pharmacy, accessing amifampridine isn't as simple as dropping off a prescription. Every major insurance company — including UnitedHealthcare, Cigna, Humana, and Aetna — requires prior authorization before they'll cover the drug. This means your neurologist must submit clinical documentation proving you have a confirmed LEMS diagnosis, including:

EMG results showing characteristic CMAP increment (>60%)

Voltage-gated calcium channel (VGCC) antibody test results

Documentation of LEMS diagnosis by a neuromuscular specialist

Cancer screening results (LEMS is often associated with small-cell lung cancer)

Standard prior authorization decisions take up to 15 days. Expedited reviews (for urgent cases) can be completed within 72 hours. Denials require appeals, which adds more time. This bureaucratic process is one of the most frustrating barriers LEMS patients face when trying to start treatment quickly.

39,483+ patients found their medications in stock

39K+

Find Amifampridine In Stock Today →

The Orphan Drug Price Problem

When Firdapse launched in 2018, Catalyst Pharmaceuticals priced it at approximately $375,000 per year — a staggering sum that drew criticism from patient advocates and legislators alike, including Senator Bernie Sanders. The controversy was amplified by the fact that amifampridine had previously been available for free through an FDA compassionate use program run by Jacobus Pharmaceutical, which had been manufacturing and distributing it at no charge since the 1990s.

Today, Firdapse remains an expensive specialty medication. However, Catalyst's patient assistance program (Catalyst Pathways) can significantly reduce out-of-pocket costs. Eligible commercially insured patients may qualify for $0 monthly copays, and patients enrolled in the program average less than $2 per month in out-of-pocket expenses. Medicare Part D patients benefit from the 2025 redesign's $2,000 annual out-of-pocket cap.

What Happened to Ruzurgi?

Some patients and caregivers have searched for Ruzurgi, a competing brand of amifampridine that was briefly approved by the FDA in 2019 specifically for children aged 6 to less than 17 years. However, Ruzurgi is no longer available in the United States. In February 2022, a court ruled that the FDA's approval of Ruzurgi had violated Catalyst's orphan drug exclusivity for Firdapse. Ruzurgi's approval was subsequently invalidated, leaving Firdapse as the sole FDA-approved amifampridine product.

Skip the calls, skip the stress.

Find Amifampridine In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Is There a Shortage of Amifampridine?

Amifampridine is not on the FDA's active drug shortage list. The challenge with accessing this medication is not a traditional shortage — it's structural. The barriers are the specialty pharmacy channel, prior authorization requirements, high cost, and the fact that the drug treats an extremely rare condition. These systemic factors make finding and filling amifampridine feel like a shortage even when the drug is technically available.

How to Get Amifampridine Filled Successfully in 2026

If you're struggling to access amifampridine, here are the most important steps:

Work with your neurologist — only a neuromuscular specialist familiar with LEMS should prescribe this medication, and they should know the specialty pharmacy network.

Contact Catalyst Pathways (1-833-422-8259) — the manufacturer's support program can help you navigate prior authorization and financial assistance.

Ask about the Firdapse Bridge Program — free medication may be available if your insurance coverage is being established.

If you're having trouble identifying which pharmacies can fill your prescription, medfinder can help — we call pharmacies on your behalf to find which ones can fill it.

For more practical tips on locating amifampridine, see our guide: How to Find Amifampridine in Stock Near You

You may also want to read: How to Save Money on Amifampridine (Firdapse) in 2026